Trial Profile

A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 As a Therapeutic Vaccine in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Jan 2026.
17 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 30 Nov 2025.
04 Apr 2024 Planned End Date changed from 31 Mar 2024 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com